Lung Cancer Trial, Recruiting NCT06047301 Sponsor: Laurie McLouth Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06047301
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with advanced non-small cell lung cancer (stage 3b, 3c, or stage 4) or extensive stage small cell lung cancer, whether newly diagnosed or returned after previous treatment
  • People aged 18 or older
  • People whose general physical functioning falls within a certain range, meaning they are able to carry out at least some daily activities (confirm with trial site for exact level required)
  • People who are between 3 and 12 weeks into a treatment plan involving infusions such as chemotherapy, immunotherapy, or a combination of both
  • People who have recorded a distress score of 3 out of 10 or higher in the past month, or who have scored 2 or higher on a specific psychological distress questionnaire called the Rotterdam Symptom Checklist

Who may not be able to join:

  • People whose cancer has spread to the brain in a way that is currently unstable, such as worsening neurological symptoms, poorly controlled seizures, or a need for increasing steroid medication
  • People with a cognitive condition such as dementia, or a psychiatric condition such as a psychotic disorder, that would make participation unsuitable
  • People who are already receiving palliative care or psychological support services at the same cancer centre
  • People who are not able to speak and read English
  • People whose hearing or vision difficulties would prevent them from taking part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Laurie McLouth, PhD, University of Kentucky

Phone: 859-562-2526

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Laurie McLouth
Registry
ClinicalTrials.gov
Start date
29 November 2023
Est. completion
31 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in PROMIS Depression Short Form Scores; Change in State Hope scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov